natgillin/translations-raw huggingface dataset:
For tumours that are locally advanced (including those that are inflammatory) or more than 2 cm wide, Herceptin is used before surgery in combination with chemotherapy and then again after surgery on its own; 
Pri lokalno napredovalih tumorjih (tudi vnetnih) ali tistih, ki so širši od dveh centimetrov, se zdravilo Herceptin uporablja pred kirurškim posegom v kombinaciji s kemoterapijo, po njem pa se uporabi samostojno;
The addition of Herceptin to chemotherapy resulted in fewer patients experiencing a reappearance of their cancer over three years. 
Zaradi dodajanja zdravila Herceptin kemoterapiji je v treh letih do vnovičnega pojava raka prišlo pri manj bolnicah.
In metastatic gastric cancer, the patients with higher levels of HER2 expression who received Herceptin by infusion into a vein survived for an average of 16.0 months, compared with 11.8 months in those receiving cisplatin and either capecitabine or 5-fluorouracil alone. 
Pri metastatskem raku želodca so bolniki z višjimi ravnmi izraženosti HER2, ki so prejemali zdravilo Herceptin v obliki infuzije v veno, preživeli povprečno 16 mesecev v primerjavi z 11,8 meseca pri tistih, ki so prejemali samo kombinacijo cisplatina in bodisi kapecitabina ali 5-fluorouracila.
The levels of the active substance were at least as high as when Herceptin is given by infusion into a vein. 
Koncentracija zdravilne učinkovine je bila vsaj tako visoka kot takrat, ko je bilo zdravilo Herceptin dano v obliki infuzije v veno.
Why has Herceptin been approved? 
Zakaj je bilo zdravilo Herceptin odobreno?
• metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or 5-fluorouracil (other anticancer medicines). 
• metastatskega raka želodca v kombinaciji s cisplatinom in bodisi kapecitabinom ali 5-fluoroacilom
In metastatic breast cancer, Herceptin given by infusion into a vein has been studied in four main studies: one looked at Herceptin on its own in 222 patients whose previous treatment had failed; two looked at Herceptin in combination with paclitaxel or docetaxel in a total of 657 patients; and one looked at the combination of Herceptin and anastrozole (an aromatase inhibitor) in 208 women who had been through the menopause. 
Pri metastatskem raku dojke so zdravilo Herceptin, dano kot infuzija v veno, proučevali v štirih glavnih študijah: v eni študiji so raziskovali samostojno uporabo zdravila Herceptin pri 222 bolnicah, pri katerih predhodna zdravljenja niso bila uspešna, drugi dve sta raziskovali uporabo zdravila Herceptin v kombinaciji s paklitakselom ali docetakselom pri skupaj 657 bolnicah, v zadnji pa so proučevali kombinacijo zdravila Herceptin in anastrozola (zaviralca aromataze) pri 208 bolnicah po končani menopavzi.
By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the tumour cells. 
Z vezavo nanjo aktivira celice imunskega sistema, ki nato uničijo tumorske celice.
A fifth study, in patients with locally advanced or inflammatory breast cancer, looked at the effect of giving Herceptin before surgery in combination chemotherapy and then again after surgery on its own. 
V peti študiji so pri bolnicah z lokalno napredovalim ali vnetnim rakom dojke proučevali učinke dodajanja zdravila Herceptin pred kirurškim posegom v kombinaciji s kemoterapijo ter nato uporabljenega samostojno po operaciji.
It is available as a powder to be made up into a solution for infusion (drip) into a vein or as a solution for injection under the skin. 
Na voljo je v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije v veno) ali raztopine za injiciranje v podkožje.
Trastuzumab has been designed to attach to HER2, which is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers. 
Trastuzumab je zasnovan tako, da se veže na beljakovino HER2, ki je preveč izražena pri približno četrtini primerov raka dojke in petini primerov raka želodca.
When given by injection under the skin, Herceptin had the same effectiveness as when given by infusion into a vein. 
Zdravilo Herceptin, injicirano pod kožo, je bilo enako učinkovito kot takrat, ko je bilo dano v obliki infuzije v veno.
Trastuzumab also stops HER2 producing signals that cause the tumour cells to grow. 
Trastuzumab beljakovini HER2 prepreči tvorjenje signalov, ki povzročajo rast tumorskih celic.
The study also compared the levels of the active substance in the blood for Herceptin given under the skin and into a vein to demonstrate that sufficient levels are obtained when given under the skin. 
V študiji so pri zdravilu Herceptin, danem pod kožo in v veno, primerjali tudi koncentracije zdravilne učinkovine v krvi, da bi dokazali, da je pri dajanju zdravila pod kožo dosežena zadostna koncentracija.
What is Herceptin used for? 
Za kaj se zdravilo Herceptin uporablja?
In metastatic gastric cancer, Herceptin given by infusion into a vein in combination with cisplatin and either capecitabine or 5-fluorouracil was compared with the same combination but without Herceptin in one main study involving 594 patients. 
Pri metastatskem raku želodca so v eni glavni študiji, v katero je bilo vključenih 594 bolnikov, zdravilo Herceptin, dano v obliki infuzije v veno, v kombinaciji s cisplatinom in bodisi kapecitabinom ali 5fluorouracilom primerjali z isto kombinacijo, vendar brez dodatka zdravila Herceptin.
In metastatic breast cancer, 15% of the patients whose previous treatment had failed responded to Herceptin given by infusion into a vein. 
Pri metastatskem raku dojk se je na zdravilo Herceptin, dano v obliki infuzije v veno, odzvalo 15 % bolnic, pri katerih predhodne vrste zdravljenja niso bile uspešne.
How has Herceptin been studied? 
Kako je bilo zdravilo Herceptin raziskano?
How does Herceptin work? 
Kako zdravilo Herceptin deluje?
What is Herceptin? 
Kaj je zdravilo Herceptin?
How is Herceptin used? 
Kako se zdravilo Herceptin uporablja?
Half of the patients received Herceptin, while the other half did not receive it. Three studies looked at the effects of giving Herceptin earlier in treatment, in combination with chemotherapy. 
V treh študijah so proučevali učinke dajanja zdravila Herceptin na začetku zdravljenja v kombinaciji s kemoterapijo.
Herceptin given as an injection under the skin was compared with Herceptin given by infusion into a vein in an additional study involving 596 patients with early breast cancer. 
V dodatni študiji, ki je vključevala 596 bolnic z zgodnjim rakom dojke, so zdravilo Herceptin, injicirano pod kožo, primerjali z zdravilom Herceptin, danim v obliki infuzije v veno.
Frequency (%) 
Pogostnost (%)
• not known: frequency cannot be estimated from the available data. 
• neznana: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov
Side effects may occur with certain frequencies, which are defined as follows: 
Neželeni učinki se pojavljajo s pogostnostjo, ki je opredeljena kot sledi:
Chinese (n=573) 
Kitajci (n = 573)
Moreover, the safety profile of Clopidogrel in this subgroup of patients did not raise any particular concern. 
Poleg tega varnostne značilnosti klopidogrela v tej podskupini bolnikov niso bile skrb zbujajoče.
The most common side effect (affects 1 to 10 patients in 100) reported with Clopidogrel is bleeding. 
Najpogostejši neželeni učinek (pojavi se pri 1 do 10 od 100 bolnikov), o katerem so poročali s klopidogrelom, je krvavitev.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/ 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA): http://www.emea.europa.eu/.
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor. 
Priložnostna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v kateremkoli 24 24 urnem obdobju) na splošno ne bi smela povzročati težav, vendar pa se morate o daljši uporabi v drugih okoliščinah posvetovati s svojim zdravnikom.
Children and adolescents Clopidogrel 1A Pharma is not intended for use in children or adolescents. 
Otroci in mladostniki Zdravilo Klopidogrel 1A Pharma ni namenjeno za uporabo pri otrocih ali mladostnikih.
In view of the lack of data, Clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke. 
Zaradi pomanjkanja podatkov klopidogrela ne moremo priporočiti v prvih 7 dneh7 dni po akutni ishemični kapi.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of Clopidogrel, sometimes after a short exposure. 
O trombotični trombocitopenični purpuri (TTP) so poročali zelo redko po uporabi klopidogrela, včasih po kratki izpostavljenosti.
Patients should inform physicians and dentists that they are taking Clopidogrel before any surgery is scheduled and before any new medicinal product is taken. 
Bolniki morajo obvestiti zdravnika in zobozdravnika, da jemljejo klopidogrel, pred vsakim načrtovanjem kirurškega posega in preden vzamejo katerokoli novo zdravilo.
Black (n=966) 
Črnci (n = 966)
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, Clopidogrel should be discontinued 7 days prior to surgery. 
Če ima bolnik predviden kirurški poseg in antitrombotični učinek začasno ni zaželen, moramo klopidogrel ukiniti 7 dni pred kirurškim posegom.
The MAH must ensure that the system of pharmacovigilance, as described in version 3.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market. 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 3,0, predstavljeni v modulu 1.8.1. vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in toliko časa, kolikor bo zdravilo v prometu.
White (n=1356) 
Belci (n = 1356)
Analysis of total mortality as a secondary endpoint did not show any significant difference between Clopidogrel (5.8%) and ASA (6.0%). 
Analiza skupne umrljivosti kot sekundarnega opazovanega dogodka ni pokazala pomembne razlike med klopidogrelom (5,8 %) in ASA (6,0 %).
Patients should be told that it might take longer than usual to stop bleeding when they take Clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolniki morajo biti obveščeni, da je lahko čas, potreben za zaustavitev krvavitve, daljši kot ponavadi, ko jemljejo klopidogrel (sam ali v kombinaciji z ASA) in da morajo poročati svojemu zdravniku o kakršnikoli neobičajni krvavitvi (mesto ali trajanje).
The incidence of severe cases was 1.4% for Clopidogrel and 1.6% for ASA. 
Incidenca hujših primerov je bila 1,4 % za klopidogrel in 1,6 % za ASA.
In addition, a subgroup analysis by age suggested that the benefit of Clopidogrel in patients over 75 years was less than that observed in patients ≤75 years. 
Razen tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih ≤ 75 let.
Some other medicines may influence the use of Clopidogrel 1A Pharmaor vice versa. 
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Klopidogrel 1A Pharma in obratno.
Do not use Clopidogrel 1A Pharma if you notice any visible sign of damage of blister or film-coated tablets. 
Ne uporabljajte zdravila Klopidogrel 1A Pharma, če ste opazili vidne znake poškodovanja pretisnega omota ali filmsko obloženih tablet.
Excipients: each tablet contains 3.80 mg hydrogenated castor oil. 
Pomožne snovi: ena tableta vsebuje 3,80 mg hidrogeniranega ricinusovega olja.
Salutas Pharma GmbH Otto-von-Guericke-Allee 1 39179 Barleben Germany 
Salutas Pharma GmbH Otto-von-Guericke-Allee 1 39179 Barleben Nemčija
Absorption is at least 50%, based on urinary excretion of Clopidogrel metabolites. 
Absorpcija je najmanj 50 %, na podlagi metabolitov klopidrogela, izločenih z urinom.
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by Clopidogrel intake. 
Vendar pa sočasna uporaba 500 mg ASA dvakrat dnevno en dan ni pomembno povečala podaljšanja časa krvavitve, sprožene z jemanjem klopidogrela.
In the fifth cohort study (n = 2,208; Simon), the increased event rate was observed only in poor metabolisers. 
V peti kohortni študiji (n = 2.208; Simon) so večji delež dogodkov ugotovili samo pri slabih presnavljalcih.
The safety and efficacy of Clopidogrel in children and adolescents have not yet been established. 
• Pediatrični bolniki Varnost in učinkovitost klopidogrela pri otrocih in mladostnikih še nista ugotovljeni.
It is unknown whether Clopidogrel is excreted in human breast milk. 
Ni znano, ali se klopidogrel pri človeku izloča v materino mlekomaterinem mleku.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of Clopidogrel. 
Če se zahteva takojšnje korigiranje podaljšanega časa krvavitve, lahko transfuzija trombocitov deluje reverzno na učinek klopidogrela.
In CLARITY and one of the cohort studies (n = 765; Trenk), cardiovascular event rates did not differ significantly by genotype. 
V CLARITY in eni od kohortnih študij (n = 765; Trenk) se deleži kardiovaskularnih dogodkov po genotipu niso bistveno razlikovali.
Pregnancy and breast-feeding It is preferable not to use this product during pregnancy and breast-feeding. 
Nosečnost in dojenje Priporočljivo je, da se tega zdravila v nosečnosti in med dojenjem ne uporablja.
As no clinical data on exposure to Clopidogrel during pregnancy are available, it is preferable not to use Clopidogrel during pregnancy as a precautionary measure. 
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrel v nosečnosti ne uporablja.
Data from the CAPRIE study indicate that phenytoin and tolbutamide can be safely co-administered with Clopidogrel. 
Podatki študije CAPRIE kažejo, da se lahko fenitoin in tolbutamid sočasno s klopidogrelom varno uporabljata.
Therapeutic experience with Clopidogrel is limited in patients with renal impairment. 
Terapevtske izkušnje s klopidogrelom so omejene pri bolnikih z ledvično okvaro.
Antacids did not modify the extent of Clopidogrel absorption. 
Antacidi niso spremenili obsega absorpcije klopidogrela.
If you stop taking Clopidogrel 1A Pharma Do not stop the treatment. 
Če ste prenehali jemati zdravilo Klopidogrel 1A Pharma Ne prekinite zdravljenja.
Other side effects reported with Clopidogrel are: -Common side effects: 
Drugi neželeni učinki, o katerih so poročali s klopidogrelom, so: - Pogosti neželeni učinki:
Specific pharmacokinetic studies performed with radiolabelled Clopidogrel have shown that the parent compound or its metabolites are excreted in the milk. 
Specifične farmakokinetične študije, izvedene z radioaktivno označenim klopidogrelom, so pokazale, da se izhodna spojina ali njeni metaboliti izločajo v mleko.
To date, diminished antiplatelet responses to Clopidogrel have been described for intermediate and poor metabolisers in 21 reported studies involving 4,520 subjects. 
Doslej so zmanjšane antitrombocitne odzive na klopidogrel opisali pri srednjih in slabih presnavljalcih v 21 opisanih študijah, ki so zajele 4.520 bolnikov.
NAME OF THE MARKETING AUTHORISATION HOLDER Acino Pharma GmbH 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Acino Pharma GmbH
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the Clopidogrel treated group and 363 (5.8%) in the placebo treated group]. 
Ta korist je bila v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom, in 363 (5,8 %) v skupini s placebom].
The association between CYP2C19 genotype and Clopidogrel treatment outcome was evaluated in 2 post hoc clinical trial analyses (substudies of CLARITY [n = 465] and TRITON-TIMI 38 [n = 1,477]) and 5 cohort studies (total n = 6,489). 
Povezavo med genotipom CYP2C19 in izidom zdravljenja s klopidogrelom so ocenili v 2 post hoc analizah kliničnih preskušanj (podštudiji CLARITY [n = 465] in TRITON-TIMI 38 [n = 1.477]) ter 5 kohortnih študijah (celotni n = 6.489).
A number of other clinical studies have been conducted with Clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions. 
Druga zdravila številne Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
For patients over 75 years of age Clopidogrel should be initiated without a loading dose. 
Pri bolnikih, ki so starejši od 75 let, je treba zdravljenje s klopidogrelom začeti brez udarnega odmerka.
Like all medicines, Clopidogrel 1A Pharma can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Klopidogrel 1A Pharma neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Apart from the specific medicinal products interaction information described above, interaction studies with Clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij o interakcijah klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo, niso izvedli.
Heparin: in a clinical study conducted in healthy subjects, Clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation. 
Heparin: v klinični študiji, izvedeni pri zdravih osebah, klopidogrel ni zahteval spremembe odmerka heparina ali spremenil učinka heparina na koagulacijo.
The efficacy of Clopidogrel was observed independently of the dose of ASA (75-325 mg once daily). 
Učinkovitost klopidogrela so opazili neodvisno od odmerka ASA (75 - 325 mg enkrat na dan).
In another study it was shown that administering Clopidogrel and omeprazole 12 hours apart did not prevent their interaction that is likely to be driven by the inhibitory effect of omeprazole on CYP2C19. 
Druga študija je pokazala, da uporaba klopidogrela in omeprazola v presledku 12 ur ne prepreči njunega medsebojnega delovanja, ki je verjetno posledica zavrtja CYP2C19 z omeprazolom.
When given to lactating rats, Clopidogrel caused a slight delay in the development of the offspring. 
Ko so ga dajali doječim podganam, je klopidogrel povzročil blago zakasnitev razvoja mladičkov.
If you take more Clopidogrel 1A Pharma than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Če ste vzeli večji odmerek zdravila Klopidogrel 1A Pharma, kot bi smeli Zaradi povečanega tveganja krvavitve se posvetujte s svojim zdravnikom ali oddelkom najbližje bolnišnične nujne zdravniške pomoči.
The safety and efficacy of Clopidogrel have been evaluated in 4 double-blind studies involving over 80,000 patients: the CAPRIE study, a comparison of Clopidogrel to ASA, and the CURE, CLARITY and COMMIT studies comparing Clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Varnost in učinkovitost klopidogrela so vrednotili v 4 dvojno slepih študijah, v katere je bilo vključenih več kot 80.000 bolnikov: študija CAPRIE je obsegala primerjavo klopidogrela in ASA, v študijah CURE, CLARITY in COMMIT pa so primerjali klopidogrel s placebom; oboje pa so bolniki dobivali v kombinaciji z ASA in drugo standardno terapijo.
Data from studies with human liver microsomes indicated that the carboxylic acid metabolite of Clopidogrel could inhibit the activity of Cytochrome P450 2C9. 
Podatki iz študij s humanimi jetrnimi mikrosomi kažejo, da lahko karboksilni kislinski metabolit klopidogrela zavira aktivnost citokroma P450 2C9.
There was no evidence of carcinogenic effect when Clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
Ni bilo dokazov o kancerogenem učinku pri dajanju klopidogrela mišim 78 tednov in podganam 104 tedne v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat višjo izpostavljenost kot pri človeku ob prejemanju kliničnega odmerka 75 mg/dan).
4.1 Therapeutic indications Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: 
Klopidogrel je indiciran pri odraslih za preprečevanje aterotrombotičnih dogodkov pri:
If you forget to take a dose of Clopidogrel 1A Pharma, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time. 
Če ste pozabili vzeti zdravilo Klopidogrel 1A Pharma Če pozabite vzeti odmerek zdravila Klopidogrel 1A Pharma in se nanj spomnite do 12 ur po ustaljenem času, takoj vzemite tableto in nato vzemite naslednjo tableto spet ob ustaljenem času jemanja.
In CAPRIE, in patients treated with either Clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
V študiji CAPRIE je bila pri bolnikih, zdravljenih bodisi s klopidogrelom ali ASA, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
To date, the impact of CYP2C19 genotype on the pharmacokinetics of the active metabolite of Clopidogrel has been evaluated in 227 subjects from 7 reported studies. 
Doslej so vpliv genotipa CYP2C19 na farmakokinetiko aktivnega presnovka klopidogrela ocenili pri 227 preiskovancih v 7 opisanih študijah.
You should take Clopidogrel 1A Pharma for as long as your doctor continues to prescribe it. 
Zdravilo Klopidogrel 1A Pharma morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel 1A Pharma in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Klopidogrel 1A Pharma v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
If you experience prolonged bleeding when taking Clopidogrel 1A Pharma. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel 1A Pharma.
Then, the usual dose is one 75 mg tablet of Clopidogrel 1A Pharma per day to be taken orally with or without food, and at the same time each day. 
Nato je običajni odmerek ena 75-mg tableta zdravila Klopidogrel 1A Pharma na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
4.6 Fertility, pregnancy and lactation 
4.6 Plodnost, nNosečnost in dojenje
Thrombolytics: the safety of the concomitant administration of Clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction. 
Trombolitiki: varnost sočasne uporabe klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ovrednotena pri bolnikih z akutnim miokardnim infarktom.
In patients with acute ST-segment elevation MI, safety and efficacy of Clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT. 
Pri bolnikih z akutnim miokardnim infarktom z elevacijo ST spojnice sta bili varnost in učinkovitost klopidogrela vrednoteni v dveh randomiziranih, s placebom kontroliranih, dvojno slepih študijah, CLARITY in COMMIT.
Driving and using machines Clopidogrel 1A Pharma is unlikely to affect your ability to drive or to use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi zdravilo Klopidogrel 1A Pharma vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.